Lakefront Biotherapeutics vs PTC Therapeutics
LKFT and PTCT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LKFT and PTCT compare
Lakefront Biotherapeutics grew revenue faster over the last twelve months (304% versus −35.1% for PTC Therapeutics).
Lakefront Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of 28.8% compared with −9.2% at PTC Therapeutics.
Lakefront Biotherapeutics scores higher on the StockData Score (7 against 5 for PTC Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LKFT | PTCT |
|---|---|---|
| Size and price | ||
| Market cap | – | $5.3B |
| Share price | $33.98 | $63.49 |
| Change, 1 year | 5.2% | −15.3% |
| Change, 5 years | −34.0% | 58.7% |
| Beta (5Y) | 0.57 | 1.09 |
| Employees | 452 | 991 |
| StockData Score | ||
| Total score | 7 (better) | 5 |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 (better) | 1 |
| Performance score | 2 | 2 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 4.6× |
| EV/EBITDA | – | 17.8× |
| P/FCF | – | 2566× |
| FCF yield | – | 0.04% |
| Fair value | – | $48.37 |
| Margin of safety | – | −31.3% |
| Growth | ||
| Revenue growth (TTM) | 304% (better) | −35.1% |
| Revenue growth, 5Y average | 18.4% | 35.4% (better) |
| Net income growth (TTM) | 333% (better) | −114% |
| EPS growth (TTM) | 335% (better) | −114% |
| Profitability | ||
| Gross margin | 97.3% | – |
| Operating margin | 26.5% (better) | 12.8% |
| Net margin | 28.8% (better) | −9.2% |
| FCF margin | −24.4% | 0.18% (better) |
| Financial health | ||
| Net debt / EBITDA | – | −7.63 |
| Interest coverage | 285× | – |
| Current ratio | 20.15 (better) | 3.27 |
| Altman Z-score | – | 0.83 |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 48.6% | 120% |
| Held by insiders | 45.1% | 3.0% |
| Insider net buying, 12 months | – | −$44.2M |
| Short interest, % of float | – | 9.6% |
Go deeper
- LKFT stock overview
- LKFT income statement
- LKFT valuation and score
- PTCT stock overview
- PTCT income statement
- PTCT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.